The retailer partnership comes as Medik8 targets more than £100 million in North American retail sales by 2029, with ambitions to become one of Sephora's top 10 skin care brands within the next three to five years. Medik8
Beginning August 11, 2026, Medik8 will debut on Sephora.com and Sephora.ca, followed by a rollout completed by August 21, 2026 to 250 U.S. Sephora stores featuring dedicated four-shelf Medik8 gondolas showcasing the brand's full assortment. In Canada, the brand will be available in all 147 Sephora locations, with 75 stores receiving dedicated branded gondolas to enhance merchandising and consumer education.
The expansion significantly increases Medik8's accessibility in North America and underscores Sephora's efforts to strengthen its position in the fast-growing clinical beauty segment, where ingredient transparency, dermatologist credibility and clinically validated efficacy are increasingly influencing purchasing decisions. While Sephora has expanded its science-led assortment with brands including SkinCeuticals, Dermalogica and Dr. Dennis Gross, Medik8 adds another premium, efficacy-focused label built around professional-grade actives and evidence-based routines.
"American consumers are more informed than ever about skin care ingredients and increasingly expect clinically proven performance, not marketing promises," said Simon Coble, CEO of Medik8. "That shift aligns directly with how Medik8 has built the brand from day one."
The retailer partnership comes as Medik8 targets more than £100 million in North American retail sales by 2029, with ambitions to become one of Sephora's top 10 skin care brands within the next three to five years. The company also plans to establish its Crystal Retinal franchise as its flagship U.S. product, building on its position as the world's top-selling retinal serum brand, according to Kline & Company.
Central to the brand's positioning is its CSA Philosophy—vitamin C and sunscreen by day, followed by vitamin A (retinal) at night—an intentionally simplified regimen designed to address the majority of visible skin aging concerns through clinically validated ingredients.
For Sephora, the launch further reinforces a broader merchandising strategy that reflects consumers' migration from "clean beauty" messaging toward clinically substantiated formulations. Retailers are increasingly emphasizing efficacy claims supported by testing, dermatologist recommendations and active ingredient education as shoppers become more sophisticated in evaluating skin care products.
"Our clients at Sephora are becoming savvier and more knowledgeable in how they shop skincare to address their individualized beauty needs," said Brooke Banwart, senior vice president of skincare merchandising at Sephora U.S. "As consumers increasingly seek expert-backed, professional-grade formulations, we're excited to partner with Medik8 as a part of our clinical skincare assortment."
The retail expansion also represents one of the first major commercial initiatives following L'Oréal Groupe's acquisition of a majority stake in Medik8, announced in June 2025. The transaction, reportedly valued at approximately €1 billion, saw private equity firm Inflexion retain a minority interest while founder Elliot Isaacs remained on the board and the existing leadership team stayed in place to preserve the brand's innovation culture.
At the time of the acquisition, L'Oréal described Medik8 as a strategically complementary addition to its Luxe portfolio, citing the brand's combination of premium positioning, accessible pricing and science-led product development. The deal followed L'Oréal's acquisition of Korean dermocosmetic brand Dr.G in late 2024, highlighting the group's continued investment in dermatological and clinically positioned beauty brands.
"We are delighted to welcome Medik8 to the L'Oréal family," said Cyril Chapuy, president of L'Oréal Luxe, when the acquisition was announced. "As a premium skin care range, with high levels of proven efficacy at an accessible price point, Medik8 perfectly complements our existing skin care portfolio."
Unlike many prestige brands that outsource formulation and manufacturing, Medik8 maintains vertically integrated operations through its innovation center outside London, where products are researched, formulated and manufactured in-house. The company says this model enables tighter control over formulation quality, ingredient consistency and clinical validation—attributes that have helped build its reputation among dermatologists, aestheticians and professional skin care practitioners.
The Sephora rollout provides L'Oréal with an opportunity to accelerate Medik8's U.S. growth while strengthening Sephora's competitive position in one of prestige beauty's fastest-growing categories. As consumers increasingly seek products backed by science rather than marketing claims, the partnership positions both companies to capitalize on the continued rise of clinical skin care.
